Dare Bioscience Inc (DARE) Stock Price, Quote & News

Company Profile

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual aro...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 926 7655

Website: darebioscience.com

Address:

3655 Nobel Drive, Suite 260, San Diego, United States

Stormy02 Apr. 23 at 7:00 PM

BIG BOYS' signature selections: $MWYN - AI expansition. Previously, the Board approved Subsidiary Formation for E-Waste Business. Possible partnership. $KULR - The shorts to go away. $AREC - Strong Buy with a 12-month price target around ~$5–$6 . $DARE - Bill & Melinda Gates Foundation Funding Up to ~$10.7 million grant, of about $3.6 million paid in late 2025. $BYND - The stock is oversold.

0 · Reply

MihaloiBobalon69 Apr. 23 at 1:40 PM

$DARE Buying more here.

0 · Reply

Guy592 Apr. 23 at 12:22 PM

$DARE condom shortage 👀

0 · Reply

SnowBison Apr. 23 at 12:50 AM

$DARE they had over $1M in Q4 2025. This quarter they have 1 more product on market so I hope revenue steady increase.

1 · Reply

Green_Party Apr. 22 at 6:59 PM

$DARE The new corporate presentation is really different than previous versions. Huge emphasis upon valuation and upcoming catalysts. Frequently mention how the "valuation is not reflected in the market." Obviously they need money, but that's always been the case. That's why you make a corporate presentation. Interesting.

0 · Reply

focafoca99 Apr. 22 at 6:32 PM

$DARE furnished an updated corporate presentation on its investor website. https://www.rapidticker.com/news/dare-sec-filing-1f9016

0 · Reply

BioBuddha Apr. 21 at 10:43 PM

$DARE made a big mistake buying this .

0 · Reply

Ceri78 Apr. 21 at 9:30 PM

$DARE sold in the morning and bought the dip just before closure

0 · Reply

BuyAndHoldStocks Apr. 21 at 9:20 PM

$DARE They can't sell to Lincoln before the vote takes place, what price do you think it will be when timing has to happen by July. De-listing risk stated in 10-k sets the time. Probably the price is well under $2. Lincoln probably sold their last purchase to you above $3. Is this brilliant and of interest to owners?

1 · Reply

Clearly_ Apr. 21 at 7:53 PM

$DARE ((3.43-1.27)/2))+1.27=2.35

1 · Reply

Daré Bioscience Earnings Call Transcript: Q4 2025

Mar 26, 2026, 4:01 PM EDT - 4 weeks ago

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

Mar 23, 2026, 8:00 AM EDT - 4 weeks ago

On National Viagra Day, Women Finally Claim Their Turn:

Mar 16, 2026, 8:00 AM EDT - 5 weeks ago

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

Mar 12, 2026, 8:00 AM EDT - 6 weeks ago

Daré Bioscience Participates in Virtual Investor “What This Means” Segment

Feb 23, 2026, 8:00 AM EST - 2 months ago

Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Dec 10, 2025, 8:00 AM EST - 4 months ago

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Nov 13, 2025, 4:30 PM EST - 5 months ago

Daré Bioscience Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:01 PM EST - 5 months ago

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 8:00 AM EST - 6 months ago

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Sep 24, 2025, 8:00 AM EDT - 7 months ago

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Aug 14, 2025, 4:30 PM EDT - 9 months ago

Daré Bioscience Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:01 PM EDT - 9 months ago

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 8:00 AM EDT - 9 months ago

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Jul 29, 2025, 8:00 AM EDT - 9 months ago

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

Jul 21, 2025, 1:47 PM EDT - 9 months ago

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Jul 14, 2025, 1:09 PM EDT - 10 months ago

Crude Oil Moves Lower; Daré Bioscience Shares Jump

Jul 14, 2025, 8:00 AM EDT - 10 months ago

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Jul 11, 2025, 8:00 AM EDT - 10 months ago

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Jun 12, 2025, 5:00 PM EDT - 11 months ago

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

May 13, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings Call Transcript: Q1 2025

May 13, 2025, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Apr 9, 2025, 4:00 PM EDT - 1 year ago

Daré Bioscience Transcript: Jones Healthcare and Technology Innovation Conference 2025

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Feb 6, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Jan 9, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 14, 2024, 4:30 PM EST - 1 year ago

Daré Bioscience Earnings Call Transcript: Q3 2024

Nov 14, 2024, 4:01 PM EST - 1 year ago

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 7, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Oct 23, 2024, 12:30 PM EDT - 1 year ago

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Oct 21, 2024, 8:05 AM EDT - 1 year ago

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Aug 12, 2024, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings Call Transcript: Q2 2024

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Jul 19, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Jul 1, 2024, 6:54 AM EDT - 1 year ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

KPRX

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Reverse Stock Split

May 14, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings Call Transcript: Q1 2024

May 14, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

May 2, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

Apr 30, 2024, 7:30 AM EDT - 2 years ago

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings Call Transcript: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

Mar 15, 2024, 2:33 PM EDT - 2 years ago

This overlooked corner of women's health could be a $350 billion market opportunity

PFE PGNY VTGN BTMD

Jan 31, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Jan 26, 2024, 4:30 PM EST - 2 years ago

Daré Bioscience Announces Executive Team and Board of Directors Changes

Jan 17, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Jan 4, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Dec 26, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Dec 20, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Dec 13, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Nov 9, 2023, 4:30 PM EST - 2 years ago

Daré Bioscience Earnings Call Transcript: Q3 2023

Nov 9, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Nov 6, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience to Participate in Three November Conferences

Nov 1, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aug 10, 2023, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings Call Transcript: Q2 2023

Aug 10, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

May 11, 2023, 4:30 PM EDT - 3 years ago

Daré Bioscience Earnings Call Transcript: Q1 2023

Mar 30, 2023, 4:30 PM EDT - 3 years ago

Daré Bioscience Earnings Call Transcript: Q4 2022

Nov 10, 2022, 1:15 PM EST - 3 years ago

Daré Bioscience Earnings Call Transcript: Q3 2022

Aug 9, 2022, 4:30 PM EDT - 4 years ago

Daré Bioscience Earnings Call Transcript: Q2 2022

Stormy02 Apr. 23 at 7:00 PM

0 · Reply

MihaloiBobalon69 Apr. 23 at 1:40 PM

$DARE Buying more here.

0 · Reply

Guy592 Apr. 23 at 12:22 PM

$DARE condom shortage 👀

0 · Reply

SnowBison Apr. 23 at 12:50 AM

$DARE they had over $1M in Q4 2025. This quarter they have 1 more product on market so I hope revenue steady increase.

1 · Reply

Green_Party Apr. 22 at 6:59 PM

0 · Reply

focafoca99 Apr. 22 at 6:32 PM

$DARE furnished an updated corporate presentation on its investor website. https://www.rapidticker.com/news/dare-sec-filing-1f9016

0 · Reply

BioBuddha Apr. 21 at 10:43 PM

$DARE made a big mistake buying this .

0 · Reply

Ceri78 Apr. 21 at 9:30 PM

$DARE sold in the morning and bought the dip just before closure

0 · Reply

BuyAndHoldStocks Apr. 21 at 9:20 PM

1 · Reply

Clearly_ Apr. 21 at 7:53 PM

$DARE ((3.43-1.27)/2))+1.27=2.35

1 · Reply

Green_Party Apr. 21 at 5:16 PM

$DARE I hope Travis's predictive abilities for DARE are as accurate as his predictions for $BIRD.

0 · Reply

Green_Party Apr. 21 at 5:14 PM

$DARE Probably selling since it looks like announcement won't be this week. But next week's around the corner...

0 · Reply

MihaloiBobalon69 Apr. 21 at 5:02 PM

$DARE Gonna yolo here see you guys in 2030!!

0 · Reply

garrincha007 Apr. 21 at 4:39 PM

$DARE Only if he bought and held these shares he would be 300% + up today 😆

2 · Reply

Guy592 Apr. 21 at 4:33 PM

$DARE this guy has been living here for years. I don't know how someone can be so pathetic. He basically lives to bash this company. Over 5 years. Get a life, man.

0 · Reply

garrincha007 Apr. 21 at 4:32 PM

$DARE loaded at 2.55, thanks for the dips guys 😁

0 · Reply

Ceri78 Apr. 21 at 4:18 PM

$DARE looks like the Algo is buying all the short tentative to push it down 😁 good sign

0 · Reply

BioBuddha Apr. 21 at 3:57 PM

$DARE why are people selling at 2.55? The warrant price is at 4 and the company is has started selling the product

0 · Reply

HoosierDaddy1728 Apr. 21 at 10:09 AM

$DARE Revenues are starting this quarter. The Shorts are going to flood this stream with everything they have before the revenues hit the books. They need "to try" to drive down share price to cover their shorts. Other bears on here want to spread misguided info because they wanted to buy but they missed out before the rise in price. In any case just know all the bears on here are wanting to buy shares at a lower price.

0 · Reply

HoosierDaddy1728 Apr. 21 at 9:53 AM

$DARE You are pointing out a brilliant funding strategy Sabrina has set up in the best interest of the shareholders. "We control the timing and amount of any sales of common stock to Lincoln Park". Most other companies when raising capital will dump their shares in the open market which drives down the share price. Dare is selling privately which does not disrupt the normal supply and demand of trading on a given day. Once Lincoln Park owns the shares it will be in their best interest for Dare share price to rise so they can sell at a profit. Bottom line, funding is required to get this incredible pipeline to market. I have never seen another CEO raise funds in the best interest of shareholders like Sabrina can do.

0 · Reply

TravisA9 Apr. 21 at 2:15 AM

$DARE Sabrina wants you to vote Yes so she can dilute shareholders another 20-30% between now and December. 14.5M outstanding and looking to climb much higher before years end! Like I’ve said for years, there will be pumps on its way to $0. Hopefully some of you took advantage and got out. Cheers https://ir.darebioscience.com/node/14441/html#i0f84b70a27484e2a8b66c1b72f3c856f_1128

0 · Reply

SpaceRunners Apr. 20 at 10:58 PM

$CMPS $BTM $IONQ $DARE %^

0 · Reply

Market Cap	30.87M
Revenue (ttm)	1.03M
Net Income (ttm)	-13.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,300.97%
Debt to Equity Ratio	0.00

Volume	332,300
Avg Vol	411,482
Day's Range	N/A - N/A
Shares Out	14.56M
Stochastic %K	23%
Beta	0.90
Analysts	Strong Sell
Price Target	$10.25